20/20 Biolabs, Inc. 8-K

What Happened
20/20 Biolabs, Inc. (AIDX) announced its financial results for the year ended December 31, 2025 by issuing a press release on March 31, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8‑K filed with the SEC on April 1, 2026. The 8‑K reflects Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release date: March 31, 2026 (furnished as Exhibit 99.1 to the Form 8‑K filed April 1, 2026).
• Reporting period: year ended December 31, 2025.
• Filing item: Item 2.02 — Results of Operations and Financial Condition.
• The filing includes the company’s press release; detailed financial figures and commentary are in Exhibit 99.1.

Why It Matters
This filing notifies investors that 20/20 Biolabs has publicly reported its full-year 2025 financial results. Investors should review the press release (Exhibit 99.1) or the company’s full SEC filings to see revenue, profit/loss, cash position, and any management commentary or forward-looking information. Those figures and commentary can affect valuation, trading decisions, and expectations for future quarterly results and guidance.